This underscores WuXi Biologics’ competitive edge on a global scale and the enduring trust from its clients, as evidenced by the significant number of new projects and the robust pipeline of ...

My rating upgrade for WuXi Biologics to a Buy has taken into consideration its latest corporate move and business disclosures. The sale of its European manufacturing facility will throw up margin ...

SHANGHAI, Jan. 2, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has ...

SHANGHAI and SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced an ...

WuXi Biologics' CEO Chris Chen has denied that the company’s sale of its less than four-year-old Ireland site is due to the threat of the US Biosecure Act, and said that the number of new ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

SHANGHAI, Jan. 2, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been ...

WuXi STA expects to hire about 500 people in the coming years to support Phase 1 of the manufacturing campus. A Chinese pharmaceutical company is moving forward with plans to build a massive $510 ...

including WuXi AppTec and WuXi Biologics, as well as BGI Group, MGI and Complete Genomics. In late December, WuXi AppTec announced a deal to sell its U.S. and U.K. cell and gene unit, known as ...

JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral with a price target of HK$20, up from HK$13, citing expected order growth and improved margins. Although the newsthat WuXi Bio ...

Wuxi Biologics (WXXWY) plans to sell its Irish vaccine facility to Merck (MRK) for around $500M ahead of potential U.S. legislation that would limit business for Chinese biotech companies ...